TBO.com - TBO is Tampa Bay Online

Bone Drug May Fight Breast Cancer

ADVERTISEMENT

The Associated Press

Published: June 1, 2008

CHICAGO - A drug to prevent bone loss during breast cancer treatment also substantially cut the risk that the cancer would return, results that left doctors excited about a possible new way to fight the disease.

It is the first large study to affirm wider anti-cancer hopes for Zometa and other bone-building drugs called bisphosphonates. Zometa, made by Novartis AG, is used now for cancers that have spread to the bone.

The new study involved 1,800 premenopausal women taking hormone treatments for early-stage breast cancer. Zometa cut by one-third the chances that cancer would recur - in their bones or anywhere else.

"This is an important finding. It may well change practice," said Claudine Isaacs, director of the clinical breast cancer program at Georgetown University's Lombardi Cancer Center.

The study was led by Michael Gnant of the Medical University of Vienna and reported Saturday at an American Society of Clinical Oncology conference in Chicago.

If a second, ongoing study also finds a benefit, doctors predict that Zometa will quickly be tested against other cancers that tend to spread, or metastasize, to bones, such as prostate and kidney cancer.

"Hugely important is whether this has to do with the fact that it just makes the bone hostile, somehow, to metastasis or if there is a more global anti-metastasis effect," said the oncology group's president, Nancy Davidson of Johns Hopkins University.

"Either of those would be good and would teach us a lot about what to do next."
Breast cancer is the most common cancer in women. About 184,450 cases and 40,930 deaths from the disease are expected in the United States this year.

Standard treatments are surgery, chemotherapy, radiation and hormone-blocking drugs.

The hormone-blockers often weaken bones, so bisphosphonates have become increasingly popular to treat this side effect. However, using them to treat the cancer itself is a very different approach.

Share this:

Loading Comments...

Email Print

ADVERTISEMENT